Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2023 Jan 25;128(2):400. doi: 10.1038/s41416-023-02161-w

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

Giuseppe Curigliano 1,2,✉,#, Geoffrey I Shapiro 3,#, Rebecca S Kristeleit 4, Albiruni R Abdul Razak 5, Stephen Leong 6, Maria Alsina 7, Antonio Giordano 8, Karen A Gelmon 9, Erica Stringer-Reasor 10, Ulka N Vaishampayan 11, Mark Middleton 12, Anthony J Olszanski 13, Hope S Rugo 14, Kenneth A Kern 15, Nuzhat Pathan 15, Rachelle Perea 15, Kristen J Pierce 16, Sarah C Mutka 17, Zev A Wainberg 18
PMCID: PMC9902525  PMID: 36697966

Correction to: British Journal of Cancer 10.1038/s41416-022-02025-9, published online 5 November 2022

The original version of this article contained an error in an affiliation. As per Italian regulation, the two affiliations for Dr. Curigliano (Istituto Europeo di Oncologia, IRCCS and University of Milan, Milano, Italy) must be separated out for proper accreditation within their systems. The original article has been corrected.

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES